Opinicus Capital Inc. Acquires Shares of 33,808 Pfizer Inc. (NYSE:PFE)

Opinicus Capital Inc. purchased a new stake in Pfizer Inc. (NYSE:PFE) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 33,808 shares of the biopharmaceutical company’s stock, valued at approximately $973,000.

Several other institutional investors and hedge funds have also recently modified their holdings of the business. Briaud Financial Planning Inc purchased a new stake in Pfizer during the 3rd quarter worth approximately $30,000. Mizuho Securities Co. Ltd. purchased a new stake in Pfizer during the 3rd quarter worth approximately $34,000. VisionPoint Advisory Group LLC increased its stake in Pfizer by 52,350.0% during the 3rd quarter. VisionPoint Advisory Group LLC now owns 1,049 shares of the biopharmaceutical company’s stock worth $35,000 after buying an additional 1,047 shares in the last quarter. GoalVest Advisory LLC increased its stake in Pfizer by 304.9% during the 4th quarter. GoalVest Advisory LLC now owns 1,077 shares of the biopharmaceutical company’s stock worth $31,000 after buying an additional 811 shares in the last quarter. Finally, Tennessee Valley Asset Management Partners purchased a new stake in Pfizer during the 4th quarter worth approximately $36,000. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Analyst Ratings Changes

PFE has been the subject of several research reports. Cantor Fitzgerald reiterated an “overweight” rating and set a $45.00 price objective on shares of Pfizer in a research note on Monday, April 15th. Guggenheim initiated coverage on Pfizer in a report on Friday, February 23rd. They set a “buy” rating and a $36.00 target price on the stock. TD Cowen cut Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 target price on the stock. in a report on Thursday, January 4th. Finally, Argus cut Pfizer from a “buy” rating to a “hold” rating in a report on Friday, March 22nd. Eleven investment analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $36.33.

Pfizer Trading Up 0.6 %

PFE traded up $0.14 during trading hours on Friday, reaching $25.40. The company’s stock had a trading volume of 46,526,457 shares, compared to its average volume of 34,120,812. Pfizer Inc. has a fifty-two week low of $25.20 and a fifty-two week high of $40.37. The stock has a market cap of $143.83 billion, a PE ratio of 70.56, a P/E/G ratio of 1.14 and a beta of 0.61. The business’s 50-day moving average is $26.96 and its 200-day moving average is $28.42. The company has a debt-to-equity ratio of 0.69, a current ratio of 0.91 and a quick ratio of 0.69.

Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.10 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.29. The company had revenue of $14.25 billion for the quarter, compared to analyst estimates of $14.37 billion. Pfizer had a return on equity of 10.88% and a net margin of 3.62%. The firm’s quarterly revenue was down 41.3% compared to the same quarter last year. During the same quarter in the previous year, the company earned $1.14 earnings per share. As a group, equities research analysts predict that Pfizer Inc. will post 2.24 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, June 14th. Shareholders of record on Friday, May 10th will be given a $0.42 dividend. This represents a $1.68 dividend on an annualized basis and a yield of 6.61%. The ex-dividend date of this dividend is Thursday, May 9th. Pfizer’s payout ratio is 466.67%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.